This continuing feature will update readers on recent developments in cardiovascular pharmacotherapy. Cardiovascular disease remains the number one killer in the US, and more clinical outcome trials have been conducted in cardiology than in any other field of medicine. Given this rapidly expanding knowledge base, pharmacists can have a significant impact on prevention and treatment — if they keep current with developments in drug therapy.
Get full access to this article
View all access options for this article.
References
1.
FeinbergW.M., BlackshearJ.L., LaupacisA.Prevalence, age distribution, and gender of patients with atrial fibrillation.Arch Intern Med.1995; 155: 469–73.
2.
WattigneyW.A., MensahG.A., CroftJ.B.Increasing trends in hospitalizations for atrial fibrillation in the United States: 1985 through 1999.Circulation.2003; 108: 711–6.
GoA.S., HylekE.M., PhillipsK.A.Prevalence of diagnosed atrial fibrillation in adults. National Implications for Rhythm Management and Stroke Prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.JAMA.2001; 285: 2370–5.
5.
UpshawC.B.Jr.Hemodynamic changes after cardioversion of chronic atrial fibrillation.Arch Intern Med.1997; 157: 1070–6.
6.
DaoudE.G., WeissR., BahuM.Effect of an irregular ventricular rhythm on cardiac output.Am J Cardiol.1996; 78: 1433–6.
7.
GoetteA., HoneycuttC., LangbergJ.J.Electrical remodeling in atrial fibrillation: Time course and mechanisms.Circulation.1996; 94: 2968–74.
8.
FusterV., RydenL.E., AsingerR.W.ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation).J Am Coll Cardiol.2001; 38: 1231–65.
9.
HohnloserS.H., KuckK.H., LillenthalJ.Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial.Lancet.2000; 356: 1789–94.
10.
The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002; 347: 1825–1833.
11.
CrijnsH.J., Van GelderI.C., Van GilstW.H.Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation and atrial flutter.Am J Cardiol.1991; 68: 335–41.
12.
Van GelderI.C., HagensV.E., BoskerH.A.for the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.N Engl J Med.2002; 347: 1834–40.
13.
SinghS.N., SinghB.N., RedaD.J.Comparison of sotalol vesus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial SAFE-T).Am J Cardiol.2003; 92: 468–72.
14.
SinghS.N., SinghB.N.Sotalol Amiodarone (atrial) Fibrillation Efficacy Trial (SAFE-T). Presented at the North American Society of Pacing and Electrophysiology, 24th Annual Scientific Sessions. May 14–17, 2003; Washington DC.
15.
FalkR.H.Management of atrial fribllation: Radical reform or modest modification? [editorial].N Engl J Med.2003;347: 1883–4.
16.
HylekE.M., GoA.S., ChangY.Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.N Engl J Med.2003; 349: 1015–16.
17.
SnowV., WeissK.B., LeFevreM.Management of newly detected atrial fibrillation: A clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians.Ann Intern Med.2003; 139: 1009–17.
